A live Q&A session covering GLP-1 drugs including Zepbound, Wegovy and Foundayo, with the host taking questions from viewers.
Recap by typeshit. Full story at DOWNSIZED.
A short Facebook share with no context on who used the peptides, where it happened or what followed.
Benzinga notes a 1.89% after-hours gain for Lilly stock, with Novo Nordisk also tagged. No further detail on what drove the move.
Mikhail Varshavski tells Fox News why protein matters, especially for GLP-1 users. He has a paid partnership with Quest Nutrition.
Gen Z use beats every other generation, and appearance was its top reason. Korean regulators are also weighing tighter controls on Wegovy and Mounjaro.
Researchers sorted about 150,000 posts in JAMA Network Open. Fatigue and insomnia also came up often, though the authors say they can't show the drug caused any of it.
Miller credits a 25% drop in weight with yearly savings in healthcare spending per person and brings up retatrutide's results.
Loading…